Abstract: A triterpenoid compound, methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate (CDDO methyl ester), has a non-crystalline, glassy solid form and a non-hydrous crystalline form that can prepared, for example, from a saturated methanol solution. The glassy form displays an enhanced bioavailability over the non-hydrous crystalline form. Each form of CDDO methyl ester is a superior candidate for use, typically in solid dosage form, for treating a variety of disease states, generally associated with inflammation.

Abstract: A triterpenoid compound, methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate (CDDO methyl ester), has a non-crystalline, glassy solid form and a non-hydrous crystalline form that can prepared, for example, from a saturated methanol solution. The glassy form displays an enhanced bioavailability over the non-hydrous crystalline form. Each form of CDDO methyl ester is a superior candidate for use, typically in solid dosage form, for treating a variety of disease states, generally associated with inflammation.

Abstract: A triterpenoid compound, methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate (CDDO methyl ester), has a non-crystalline, glassy solid form and a non-hydrous crystalline form that can prepared, for example, from a saturated methanol solution. The glassy form displays an enhanced bioavailability over the non-hydrous crystalline form. Each form of CDDO methyl ester is a superior candidate for use, typically in solid dosage form, for treating a variety of disease states, generally associated with inflammation.

Abstract: A triterpenoid compound, methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate (CDDO methyl ester), has a non-crystalline, glassy solid form and a non-hydrous crystalline form that can prepared, for example, from a saturated methanol solution. The glassy form displays an enhanced bioavailability over the non-hydrous crystalline form. Each form of CDDO methyl ester is a superior candidate for use, typically in solid dosage form, for treating a variety of disease states, generally associated with inflammation.

Abstract: A triterpenoid compound, methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate (CDDO methyl ester), has a non-crystalline, glassy solid form and a non-hydrous crystalline form that can prepared, for example, from a saturated methanol solution. The glassy form displays an enhanced bioavailability over the non-hydrous crystalline form. Each form of CDDO methyl ester is a superior candidate for use, typically in solid dosage form, for treating a variety of disease states, generally associated with inflammation.

Abstract: A triterpenoid compound, methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate (CDDO methyl ester), has a non-crystalline, glassy solid form and a non-hydrous crystalline form that can prepared, for example, from a saturated methanol solution. The glassy form displays an enhanced bioavailability over the non-hydrous crystalline form. Each form of CDDO methyl ester is a superior candidate for use, typically in solid dosage form, for treating a variety of disease states, generally associated with inflammation.

Abstract: A device for measuring optical power simultaneously for two or more spectral regions. Two or more photodetectors, such as photodiodes, measure the pulse energy and/or power emitted by a laser having output in two or more spectral regions. The laser radiation is transmitted through a diffuser or beamsplitter, then filtered and/or attenuated so that light from each respective spectral region is incident on the active region of a photodiode. The device also includes electronic circuitry with one or more operational amplifiers for each photodiode, integrators and analog-to-digital converters. In a preferred embodiment, the device also includes a microprocessor to provide noise reduction and calibration functions for each photodiode output, and to drive a display or readout.

Abstract: A nicotine product having a nicotine release rate of not less than 70% over a 10 minute period as well as a process to produce such product. Such product is produced by a process comprising the steps of (a) preparing an aqueous solution of an organic polyol; (b) mixing said aqueous solution of the organic polyol with a cation exchange resin selected from the group consisting of (i)—a methacrylic, weakly acidic type of resin containing carboxylic functional groups (ii)—polystyrene, strongly acidic type of resin containing sulfonic functional groups and (iii)—polystyrene, intermediate acidic type of resin containing phosphonic functional groups thereby forming a cation exchange resin mixture having some of its ion exchange sites partially blocked with said polyol; (c) admixing with said mixture of step (b) an aqueous solution of nicotine to form a nicotine-coated cation exchange resin admixture; and (d) removing water from said admixture.

Abstract: A nicotine product having a nicotine release rate of not less than 70% over a 10 minute period as well as a process to produce such product.

Abstract: The present invention discloses novel immunogens, antibodies prepared from such immunogens, and labeled reagents useful in immunoassays for the detection and quantification of testosterone in a test sample. Also disclosed are immunoassays using these reagents and methods for synthesizing these reagents. The immunoassays are preferably microparticle enzyme immunoassays (MEIAs) and fluorescence polarization immunoassays (FPIAs). Further disclosed are novel starting materials for making the above novel immunogens and labeled reagents. Methods for making the novel immunogens and labeled reagents from the novel starting materials are also disclosed.

Abstract: The present invention discloses a process for making 1-.alpha.-(carboxyalkyl)testosterone having the following formula: ##STR1## The process involves protecting the 17 position of 1,4-androstadien-17 .beta.-ol-3-one with TBDMS, alkylating with an alkenylmagnesium bromide and ozonolyzing the resulting ether. The resulting product is oxidized with sodium hypochloride followed by removal of the TBDMS protecting group with aqueous hydrofluoric acid in acetonitrile to produce the 1-.alpha.-(carboxyalkyl)-testosterone.

Abstract: A Position 1 immunogen having the following formula: ##STR1## wherein: (a) P represents an immunogenic carrier material(b) X represents a linking moiety wherein --X--P is attached to a testosterone derivative(c) n is from 1 to 10, inclusive(d) the degree of substitution of P by the testosterone derivative is from 1 to 100%, inclusive.

Abstract: The present invention discloses novel immunogens, antibodies prepared from such immunogens, and labeled reagents useful in immunoassays for the detection and quantification of testosterone in a test sample. Also disclosed are immunoassays using these reagents and methods for synthesizing these reagents. The immunoassays are preferably microparticle enzyme immunoassays (MEIAs) and fluorescence polarization immunoassays (FPIAs). Further disclosed are novel starting materials for making the above novel immunogens and labeled reagents. Methods for making the novel immunogens and labeled reagents from the novel starting materials are also disclosed.

Abstract: Disclosed is a substantially optically pure hapten, useful in an immunoassay for cotinine. The hapten corresponds to a specified structural formula (I). In formula (I) X is a straight or branched chain, saturated or unsaturated, divalent radical covalently bonded to a pyridyl ring at the number 2-, 4-, 5- or 6-position. The divalent radical, X, has from 1 to 10 carbon atoms wherein the chain of the divalent radical optionally may contain 1 or 2 hetero atoms selected from members of the group consisting of S, O and NZ in which Z represents a C.sub.1 to C.sub.3 alkyl group. In formula (I), n=1 or 0, and Q is a functional group selected from --COOH, --NH.sub.2 (provided that n does not equal 0), --C(O)NHNH.sub.2, --O(CO)Cl, --CHO, --NCS or --NCO.Also disclosed is an immunogen derived from the hapten as well as an antibody raised in response to an immunogen derived from the hapten.

Abstract: A fluorescence polarization immunoassay for detecting the presence of methadone in a test sample is provided, based upon competition between methadone and a fluorescently labeled tracer for the binding sites on an antibody specific for methadone. The concentration of methadone in the sample determines the amount of tracer that binds to the antibody. The amount of tracer-antibody complex formed can be quantitatively measured and is inversely proportional to the quantity of methadone in the sample. Tracers used as reagents and immunogens used to raise antibodies for use as reagents are also disclosed.